uniQure to Participate in Multiple Upcoming Industry Conferences in February

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Jan. 31, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in February:

• 13^th Annual Congress of the European Association for Hemophilia and Allied Disorders (EAHAD), February 5 – 7, The Hague, the Netherlands.
  
  
  
  • uniQure will deliver 7 presentations on the development of its gene therapy candidates etranacogene dezaparvovec for hemophilia B, AMT-180 for hemophilia A, and its technology platform.
  
  • Further details on the company’s presentations will follow closer to conference. 
  
  
  
  
• 16^th Annual WORLD Symposium, February 10 – 13, Orlando, FL.
  
  
  
  • Ying Poi Liu, Ph.D., senior scientist at uniQure, will present on the development of an AAV5-based gene therapy for Fabry disease, on Tuesday, February 11, from 4:30 – 6:30 p.m. ET.
  
   
• CHDI 15^th Annual Huntington’s Therapeutics Conference, February 22 – 25, Palm Springs, CA.
  
  
  
  • uniQure will deliver 5 presentations on the development of AMT-130, the company’s AAV-gene therapy candidate for the treatment of Huntington’s disease.
  
  • Further details on the company’s presentations will follow closer to the conference.
  
   
• 64^th Annual Meeting of the Society of Thrombosis and Haemostasis Research – GTH 2020, February 18 – 21, Bremen, Germany.
  
  
  
  • Professor Wolfgang Miesbach, M.D., Ph.D., of the University Hospital Frankfurt in Germany, will present 12-month follow-up data on the company’s gene therapy candidate etranacogene dezaparvovec in hemophilia B, as well as four-year follow-up data on AMT-060, also in patients with hemophilia B.
  
  
  
  
• 9^th Annual SVB Leerink Global Healthcare Conference, February 25 – 27, New York City.
  
  
  
  • , chief executive officer at uniQure, will participate in a fireside chat with research analyst Joseph Schwarz, on Tuesday, February 25, from 2:30 – 2:55 p.m. ET. The live webcast of the corporate update can be accessed through the link displayed in the . The webcast replay will be available for at least 72 hours following the live event.
  
  • Members of uniQure’s management team will participate in one-on-one investor meetings throughout the day on Tuesday, February 25.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. 

uniQure Contacts: